CRISPR Therapeutics AG (CRSP) Earnings History
Net Loss12 years of earnings data (2014–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
CRISPR Therapeutics AG (CRSP) Earnings Overview
As of July 7, 2026, CRISPR Therapeutics AG (CRSP) reported trailing twelve-month net income of -$569M, reflecting -49.1% year-over-year growth. The company earned $-5.92 per diluted share over the past four quarters, with a net profit margin of -16569.8%.
Looking at the long-term picture, CRSP's historical earnings data spans multiple years. The company achieved its highest annual net income of $378M in fiscal 2021.
CRISPR Therapeutics AG is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EDIT (-$109M net income, -395.0% margin), NTLA (-$395M net income, -609.9% margin), BEAM (-$65M net income, -57.2% margin), CRSP has room to improve margins relative to the peer group. Compare CRSP vs EDIT →
CRSP Earnings vs Peers
Earnings metrics vs comparable public companies
CRSP Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$582M | -58.8% | -$568M | $-6.47 | -16569.8% | -16191.4% |
| 2024 | -$366M | -138.4% | -$467M | $-4.34 | -1046.4% | -1333.0% |
| 2023 | -$154M | +76.4% | -$223M | $-1.94 | -41.5% | -60.1% |
| 2022 | -$650M | -272.2% | -$673M | $-8.36 | -149122.7% | -154394.7% |
| 2021 | $378M | +208.3% | $374M | $4.70 | 41.4% | 40.9% |
| 2020 | -$349M | -621.8% | -$354M | $-5.29 | -48520.9% | -49295.5% |
| 2019 | $67M | +140.5% | $47M | $1.17 | 23.1% | 16.1% |
| 2018 | -$165M | -141.4% | -$159M | $-3.44 | -5281.1% | -5087.8% |
| 2017 | -$68M | -194.6% | -$65M | $-1.71 | -166.7% | -157.7% |
| 2016 | -$23M | +10.2% | -$68M | $-1.89 | -449.3% | -1319.3% |
| 2015 | -$26M | -279.8% | -$26M | $-0.88 | -10456.7% | -10416.6% |
| 2014 | -$7M | - | -$7M | $-0.23 | - | - |
Download Data
Export CRSP earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRSP — Frequently Asked Questions
Quick answers to the most common questions about buying CRSP stock.
What is CRSP earnings per share (EPS)?
CRSP trailing twelve-month (TTM) diluted EPS is $-5.92, reflecting -49.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2014 to 2025 is available in the table on this page.
What is CRISPR Therapeutics AG's net income?
CRISPR Therapeutics AG (CRSP) trailing twelve-month net income is $-569M as of 2025. Earnings declined -49.1% year-over-year.
Is CRSP profitable?
CRSP is not currently profitable on a TTM basis, reporting a net loss of $-569M. Net margin is -16569.8%. Investors should monitor for a return to profitability.
What is CRSP's earnings growth rate?
CRSP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2014 to 2025.
What are CRSP's profit margins?
CRISPR Therapeutics AG net profit margin is -16569.8%, operating margin is -16191.4%, and gross margin is -6537.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -30.2%.
Is CRSP growing earnings?
CRSP earnings are declining — EPS fell -49.1% year-over-year. TTM net income dropped to $-569M. This contrasts with the 5-year CAGR of N/A.
What was CRSP's best earnings year?
CRISPR Therapeutics AG's highest annual net income on record is $378M, achieved in fiscal year 2021. Earnings history on this page spans 2014 to 2025 and includes all annual and quarterly figures.
What were CRSP's earnings last quarter?
CRSP's most recent reported quarter was Q1 2026. Net income was $-123M with diluted EPS of $-1.28. For a full breakdown of all quarters, see the quarterly earnings table on this page.